Steven Cohen Immunic, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.13 - $10.8 $689,689 - $6.59 Million	-610,345 Reduced 46.06%	714,655 $1 Million
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $1.88 Million - $7.35 Million	600,000 Added 82.76%	1,325,000 $4.6 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $734,000 - $1.03 Million	100,000 Added 16.0%	725,000 $6.94 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $5.03 Million - $8.31 Million	625,000 New	625,000 $5.53 Million
Q2 2021 Aug 16, 2021	SELL	$11.76 - $16.85 $5.09 Million - $7.3 Million	-433,047 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.21 - $25.3 $3.25 Million - $5.78 Million	228,547 Added 111.76%	433,047 $6.9 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $3.03 Million - $4.17 Million	204,500 New	204,500 $3.13 Million
Q3 2020 Nov 16, 2020	SELL	$11.74 - $22.0 $2.05 Million - $3.85 Million	-175,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.67 - $15.86 $992,250 - $2.78 Million	175,000 New	175,000 $2.12 Million

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $30.6M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.